Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 108

1.

Targeted sequencing to identify novel genetic risk factors for deep vein thrombosis: a study of 734 genes.

de Haan HG, van Hylckama Vlieg A, Lotta LA, Gorski MM, Bucciarelli P, Martinelli I, Baglin TP, Peyvandi F, Rosendaal FR; INVENT consortium.

J Thromb Haemost. 2018 Dec;16(12):2432-2441. doi: 10.1111/jth.14279. Epub 2018 Oct 16.

2.

Targeting activated protein C to treat hemophilia.

Polderdijk SGI, Baglin TP, Huntington JA.

Curr Opin Hematol. 2017 Sep;24(5):446-452. doi: 10.1097/MOH.0000000000000364. Review.

3.

Endoscopy in patients on antiplatelet or anticoagulant therapy, including direct oral anticoagulants: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guidelines.

Veitch AM, Vanbiervliet G, Gershlick AH, Boustiere C, Baglin TP, Smith LA, Radaelli F, Knight E, Gralnek IM, Hassan C, Dumonceau JM.

Endoscopy. 2016 Apr;48(4):c1. doi: 10.1055/s-0042-122686. Epub 2017 Jan 23. No abstract available.

PMID:
28114689
4.

Design and characterization of an APC-specific serpin for the treatment of hemophilia.

Polderdijk SG, Adams TE, Ivanciu L, Camire RM, Baglin TP, Huntington JA.

Blood. 2017 Jan 5;129(1):105-113. doi: 10.1182/blood-2016-05-718635. Epub 2016 Oct 27.

5.

Endoscopy in patients on antiplatelet or anticoagulant therapy, including direct oral anticoagulants: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guidelines.

Veitch AM, Vanbiervliet G, Gershlick AH, Boustiere C, Baglin TP, Smith LA, Radaelli F, Knight E, Gralnek IM, Hassan C, Dumonceau JM.

Endoscopy. 2016 Apr;48(4):385-402. doi: 10.1055/s-0042-102652. Epub 2016 Feb 18. Erratum in: Endoscopy. 2016 Apr;48(4):c1.

6.

Endoscopy in patients on antiplatelet or anticoagulant therapy, including direct oral anticoagulants: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guidelines.

Veitch AM, Vanbiervliet G, Gershlick AH, Boustiere C, Baglin TP, Smith LA, Radaelli F, Knight E, Gralnek IM, Hassan C, Dumonceau JM.

Gut. 2016 Mar;65(3):374-89. doi: 10.1136/gutjnl-2015-311110.

7.

Prolonged clot lysis time increases the risk of a first but not recurrent venous thrombosis.

Karasu A, Baglin TP, Luddington R, Baglin CA, van Hylckama Vlieg A.

Br J Haematol. 2016 Mar;172(6):947-53. doi: 10.1111/bjh.13911. Epub 2016 Jan 15. Review.

PMID:
26773756
8.

Discovery and characterization of an antibody directed against exosite I of thrombin.

Baglin TP, Langdown J, Frasson R, Huntington JA.

J Thromb Haemost. 2016 Jan;14(1):137-42. doi: 10.1111/jth.13171. Epub 2015 Dec 29.

9.

The risk of a first and a recurrent venous thrombosis associated with an elevated D-dimer level and an elevated thrombin potential: results of the THE-VTE study: reply.

van Hylckama Vlieg A, Baglin TP.

J Thromb Haemost. 2015 Dec;13(12):2286-7. doi: 10.1111/jth.13170. Epub 2015 Oct 29. No abstract available.

10.

The risk of a first and a recurrent venous thrombosis associated with an elevated D-dimer level and an elevated thrombin potential: results of the THE-VTE study.

van Hylckama Vlieg A, Baglin CA, Luddington R, MacDonald S, Rosendaal FR, Baglin TP.

J Thromb Haemost. 2015 Sep;13(9):1642-52. doi: 10.1111/jth.13043. Epub 2015 Aug 27.

11.

A hereditary bleeding disorder resulting from a premature stop codon in thrombomodulin (p.Cys537Stop).

Langdown J, Luddington RJ, Huntington JA, Baglin TP.

Blood. 2014 Sep 18;124(12):1951-6. doi: 10.1182/blood-2014-02-557538. Epub 2014 Jul 21.

12.
13.

Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Garcia DA, Baglin TP, Weitz JI, Samama MM.

Chest. 2012 Feb;141(2 Suppl):e24S-e43S. doi: 10.1378/chest.11-2291. Review. Erratum in: Chest. 2012 May;141(5):1369. Dosage error in article text. Chest. 2013 Aug;144(2):721. Dosage error in article text.

14.

Venous thromboembolism in oesophago-gastric carcinoma: incidence of symptomatic and asymptomatic events following chemotherapy and surgery.

Rollins KE, Peters CJ, Safranek PM, Ford H, Baglin TP, Hardwick RH.

Eur J Surg Oncol. 2011 Dec;37(12):1072-7. doi: 10.1016/j.ejso.2011.08.140. Epub 2011 Sep 16.

PMID:
21925829
15.

Non-malignant haematology research in the UK: looking forward to new opportunities.

Collins PW, Baglin TP, Dang R, Evans G, Greaves M, Laffan M, Pasi KJ, Rose P, Stanworth S, Toh CH.

Br J Haematol. 2010 Sep;150(6):732-6.

PMID:
21105240
16.

Guidelines on travel-related venous thrombosis.

Watson HG, Baglin TP.

Br J Haematol. 2011 Jan;152(1):31-4. doi: 10.1111/j.1365-2141.2010.08408.x. Epub 2010 Nov 18. Review.

PMID:
21083651
17.

Incidental pulmonary emboli in lymphoma patients are associated with aggressive disease and poor prognosis.

Grigoropoulos NF, Shaw AS, Hampson FA, Baglin TP, Follows GA.

J Thromb Haemost. 2010 Dec;8(12):2835-6. doi: 10.1111/j.1538-7836.2010.04061.x. No abstract available.

18.

The critical role of hinge-region expulsion in the induced-fit heparin binding mechanism of antithrombin.

Langdown J, Belzar KJ, Savory WJ, Baglin TP, Huntington JA.

J Mol Biol. 2009 Mar 13;386(5):1278-89.

19.

Guidelines for the management of anticoagulant and antiplatelet therapy in patients undergoing endoscopic procedures.

Veitch AM, Baglin TP, Gershlick AH, Harnden SM, Tighe R, Cairns S; British Society of Gastroenterology; British Committee for Standards in Haematology; British Cardiovascular Intervention Society.

Gut. 2008 Sep;57(9):1322-9. doi: 10.1136/gut.2007.142497. Epub 2008 May 9. Review. No abstract available.

PMID:
18469092
20.

Proof of principle of potential clinical utility of multiple SNP analysis for prediction of recurrent venous thrombosis.

van Hylckama Vlieg A, Baglin CA, Bare LA, Rosendaal FR, Baglin TP.

J Thromb Haemost. 2008 May;6(5):751-4. doi: 10.1111/j.1538-7836.2008.02920.x. Epub 2008 Jan 31.

21.

Elevated endogenous thrombin potential is associated with an increased risk of a first deep venous thrombosis but not with the risk of recurrence.

van Hylckama Vlieg A, Christiansen SC, Luddington R, Cannegieter SC, Rosendaal FR, Baglin TP.

Br J Haematol. 2007 Sep;138(6):769-74.

PMID:
17760809
22.

The risk of venous thrombosis associated with a high endogenous thrombin potential in the absence and presence of activated protein C.

Brandts A, van Hylckama Vlieg A, Rosing J, Baglin TP, Rosendaal FR.

J Thromb Haemost. 2007 Feb;5(2):416-8. Epub 2006 Nov 17. No abstract available.

23.

Safety indicators for inpatient and outpatient oral anticoagulant care: [corrected] Recommendations from the British Committee for Standards in Haematology and National Patient Safety Agency.

Baglin TP, Cousins D, Keeling DM, Perry DJ, Watson HG.

Br J Haematol. 2007 Jan;136(1):26-9. Epub 2006 Nov 20. No abstract available. Erratum in: Br J Haematol. 2007 Feb;136(4):681.

PMID:
17116128
24.

Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation.

Collins PW, Hirsch S, Baglin TP, Dolan G, Hanley J, Makris M, Keeling DM, Liesner R, Brown SA, Hay CR; UK Haemophilia Centre Doctors' Organisation.

Blood. 2007 Mar 1;109(5):1870-7. Epub 2006 Oct 17.

PMID:
17047148
25.

Crystal structure of monomeric native antithrombin reveals a novel reactive center loop conformation.

Johnson DJ, Langdown J, Li W, Luis SA, Baglin TP, Huntington JA.

J Biol Chem. 2006 Nov 17;281(46):35478-86. Epub 2006 Sep 13.

26.

Platelet mass has prognostic value in patients with myelodysplastic syndromes.

Bowles KM, Warner BA, Baglin TP.

Br J Haematol. 2006 Oct;135(2):198-200. Epub 2006 Aug 25.

PMID:
16939490
27.

Predicting response to recombinant factor VIIa in non-haemophiliac patients with severe haemorrhage.

Bowles KM, Callaghan CJ, Taylor AL, Harris RJ, Pettigrew GJ, Baglin TP, Park GR.

Br J Anaesth. 2006 Oct;97(4):476-81. Epub 2006 Aug 16.

28.

Allosteric activation of antithrombin is independent of charge neutralization or reversal in the heparin binding site.

Langdown J, Carter WJ, Baglin TP, Huntington JA.

FEBS Lett. 2006 Aug 21;580(19):4709-12. Epub 2006 Jul 26.

29.

Guidelines on use of vena cava filters.

British Committee for Standards in Haematology Writing Group, Baglin TP, Brush J, Streiff M.

Br J Haematol. 2006 Sep;134(6):590-5. Epub 2006 Jul 26. No abstract available.

PMID:
16869824
31.
32.

Guidelines on oral anticoagulation (warfarin): third edition--2005 update.

Baglin TP, Keeling DM, Watson HG; British Committee for Standards in Haematology.

Br J Haematol. 2006 Feb;132(3):277-85. No abstract available.

PMID:
16409292
33.

Platelet size has diagnostic predictive value in patients with thrombocytopenia.

Bowles KM, Cooke LJ, Richards EM, Baglin TP.

Clin Lab Haematol. 2005 Dec;27(6):370-3.

PMID:
16307537
34.

Warfarin sensitivity and genetic polymorphisms: should pharmacokinetic screening be part of anticoagulant dosing decisions?

Baglin TP.

Clin Adv Hematol Oncol. 2003 Nov;1(11):656-7. No abstract available.

PMID:
16258463
35.

Is there a true difference in recurrence rate of deep venous thrombosis between men and women?

van Hylckama Vlieg A, Baglin CA, Baglin TP.

J Thromb Haemost. 2005 Sep;3(9):2113-4. No abstract available.

36.

Identification and removal of a promiscuous CD4+ T cell epitope from the C1 domain of factor VIII.

Jones TD, Phillips WJ, Smith BJ, Bamford CA, Nayee PD, Baglin TP, Gaston JS, Baker MP.

J Thromb Haemost. 2005 May;3(5):991-1000.

37.

The heparin binding properties of heparin cofactor II suggest an antithrombin-like activation mechanism.

O'Keeffe D, Olson ST, Gasiunas N, Gallagher J, Baglin TP, Huntington JA.

J Biol Chem. 2004 Nov 26;279(48):50267-73. Epub 2004 Sep 15.

38.

Allosteric activation of antithrombin critically depends upon hinge region extension.

Langdown J, Johnson DJ, Baglin TP, Huntington JA.

J Biol Chem. 2004 Nov 5;279(45):47288-97. Epub 2004 Aug 23.

39.

Targeting thrombin--rational drug design from natural mechanisms.

Huntington JA, Baglin TP.

Trends Pharmacol Sci. 2003 Nov;24(11):589-95. Review.

PMID:
14607082
40.

Travellers' thrombosis and economy class syndrome: incidence, aetiology and prevention.

O'Keeffe DJ, Baglin TP.

Clin Lab Haematol. 2003 Oct;25(5):277-81. Review.

PMID:
12974716
41.

A novel role for CD36 in VLDL-enhanced platelet activation.

Englyst NA, Taube JM, Aitman TJ, Baglin TP, Byrne CD.

Diabetes. 2003 May;52(5):1248-55.

42.

Crystal structures of native and thrombin-complexed heparin cofactor II reveal a multistep allosteric mechanism.

Baglin TP, Carrell RW, Church FC, Esmon CT, Huntington JA.

Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11079-84. Epub 2002 Aug 8.

43.

The use of oral vitamin K for reversal of over-warfarinization.

Watson HG, Baglin TP, Makris M.

Br J Haematol. 2002 Jan;116(1):237. No abstract available.

PMID:
11848091
44.

Suppressing thrombin generation is compatible with the development of atherosclerosis in mice.

Grainger DJ, McWilliam NA, Baglin TP, Byrne CD.

Thromb Res. 2001 Apr 1;102(1):71-80.

PMID:
11323017
45.
46.

The diagnosis and management of factor VIII and IX inhibitors: a guideline from the UK Haemophilia Centre Doctors' Organization (UKHCDO).

Hay CR, Baglin TP, Collins PW, Hill FG, Keeling DM.

Br J Haematol. 2000 Oct;111(1):78-90. No abstract available.

PMID:
11091185
47.

The C536T transition in the tissue factor pathway inhibitor gene is not a common cause of venous thromboembolic disease in the UK population.

Evans GD, Langdown J, Brown K, Baglin TP.

Thromb Haemost. 2000 Mar;83(3):511. No abstract available.

PMID:
10744164
48.

A randomized trial of solvent/detergent-treated and standard fresh-frozen plasma in the coagulopathy of liver disease and liver transplantation.

Williamson LM, Llewelyn CA, Fisher NC, Allain JP, Bellamy MC, Baglin TP, Freeman J, Klinck JR, Ala FA, Smith N, Neuberger J, Wreghitt TG.

Transfusion. 1999 Nov-Dec;39(11-12):1227-34.

PMID:
10604250
49.

Solvent/detergent fresh frozen plasma as primary treatment of acute thrombotic thrombocytopenic purpura.

Evans G, Llewelyn C, Luddington R, Baglin TP, Williamson LM.

Clin Lab Haematol. 1999 Apr;21(2):119-23.

PMID:
10342071
50.

Risk of venous thromboembolism associated with the common hereditary haemochromatosis Hfe gene (C282Y) mutation.

Brown K, Luddington R, Taylor SA, Lillicrap DP, Baglin TP.

Br J Haematol. 1999 Apr;105(1):95-7.

PMID:
10233369

Supplemental Content

Loading ...
Support Center